See more : Toyota Motor Corp (TOM.SG) Income Statement Analysis – Financial Results
Complete financial analysis of Marvel Biosciences Corp. (MRVL.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marvel Biosciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Wam Alternative Assets Limited (WMA.AX) Income Statement Analysis – Financial Results
- Ekwan X Inc. (EKWX) Income Statement Analysis – Financial Results
- Weis Markets, Inc. (WMK) Income Statement Analysis – Financial Results
- Polyard Petroleum International Group Limited (8011.HK) Income Statement Analysis – Financial Results
- Raymond Industrial Limited (0229.HK) Income Statement Analysis – Financial Results
Marvel Biosciences Corp. (MRVL.V)
About Marvel Biosciences Corp.
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 887.52K | 1.38M | 613.10K | 265.20K | 0.00 |
| Gross Profit | -887.52K | -1.38M | -613.10K | -265.20K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 887.52K | 1.38M | 613.10K | 265.20K | 0.00 |
| General & Administrative | 1.10M | 1.12M | 635.27K | 750.90K | 0.00 |
| Selling & Marketing | 312.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.41M | 1.12M | 635.27K | 750.90K | 100.05K |
| Other Expenses | 0.00 | 0.00 | -35.00K | 0.00 | 0.00 |
| Operating Expenses | 2.32M | 1.17M | 485.04K | 689.57K | 100.05K |
| Cost & Expenses | 2.32M | 2.55M | 1.10M | 954.77K | 100.05K |
| Interest Income | 0.00 | 0.00 | 239.00 | 403.00 | 2.01K |
| Interest Expense | 34.59K | 1.55K | 1.97K | 719.00 | 0.00 |
| Depreciation & Amortization | 66.92K | 152.00 | 185.00 | 413.00 | 171.86K |
| EBITDA | -2.25M | -2.51M | -1.25M | -1.02M | -100.05K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.32M | -2.54M | 806.33K | -954.20K | -100.05K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 27.54K | -5.86K | -1.79M | 63.36K | 109.36K |
| Income Before Tax | -2.29M | -2.55M | -3.04M | -955.66K | -98.04K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.86K | 1.91M | 886.00 | -171.86K |
| Net Income | -2.29M | -2.55M | -3.04M | -955.66K | -98.04K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.08 | -0.17 | -0.13 | -0.03 |
| EPS Diluted | -0.06 | -0.08 | -0.17 | -0.13 | -0.03 |
| Weighted Avg Shares Out | 39.66M | 32.76M | 17.70M | 7.37M | 2.98M |
| Weighted Avg Shares Out (Dil) | 39.66M | 32.76M | 17.70M | 7.37M | 2.98M |
Source: https://incomestatements.info
Category: Stock Reports